Coral Laboratories Ltd (CORALAB) — shareholding pattern, promoter holding, financials and share price
About Coral Laboratories Ltd (CORALAB)
Coral Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as CORALAB and on the BSE under scrip code 524506. Its ISIN is INE683E01017.
Incorporated in 1994, Coral Laboratories Ltd is in the business of pharmaceutical formulations [1]
Coral Laboratories Limited (CLL) is a pharmaceutical company focused on manufacturing generic branded, nutraceuticals, OTC, and herbal medicines across India.
The company operates three production facilities located in Daman and Dehradun, enhancing its manufacturing capacity and scope.
Listed peers in Pharmaceuticals: Nectar Lifescience Ltd, Kerala Ayurveda Ltd, Syschem (India) Ltd, Brooks Laboratories Ltd, Gujarat Inject (Kerala) Ltd, Achyut Healthcare Ltd.
Valuation & Returns
10 Jul 2026At ₹611.99 a share on 10 Jul 2026, Coral Laboratories Ltd (CORALAB) was valued at a price-to-earnings ratio of 13.35x against an industry P/E of 36.41x and a price-to-book of 1.09x on a book value of ₹563.19 per share as of Mar 2025. Solomo computes return on equity of 8.14% and return on capital employed of 11.38% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 13.35x
- Industry P/E
- 36.41x
- P/B
- 1.09x
- EPS (TTM)
- ₹45.85
- Book value / share
- ₹563.19
- ROE
- 8.14%
- ROCE
- 11.38%
- ROA
- 7.14%
- Debt / equity
- 0.02x
- Dividend yield
- 0.25%
- EBITDA margin
- 29.6%
- 52-week range
- ₹360 – ₹659
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Coral Laboratories Ltd (CORALAB) reported revenue of ₹86 crore, net profit of ₹16 crore and earnings per share of ₹45.85. That compares with revenue of ₹115 crore and net profit of ₹24 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹26.48 crore and net profit ₹5.22 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 76 | 78 | 84 | 115 | 86 |
| Net profit (₹ cr) | 9 | 6 | 16 | 24 | 16 |
| EPS (₹) | 25.33 | 18.05 | 44.2 | 67.63 | 45.85 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 4.32% | 10.26% | 15.00% | 37.47% |
| Profit growth | 7.69% | 27.64% | 38.74% | 53.01% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 71.51% of Coral Laboratories Ltd (CORALAB) (unchanged from the previous quarter). Market capitalisation was ₹219 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2001.
Largest disclosed public shareholders in Jun 2026: Investor Education And Protection Fund Authority Ministry Of Corporate Affairs 2.64%, Meeta Samir Sheth 1.84%, Pooja Bhagwandas 1.83%, HUF 1.17%, Neelam Mital 1.14%, Noetic Finance Private Limited 1.06%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 71.51% | - | - | - | 28.49% |
| Mar 2026 | 71.51% | - | - | - | 28.49% |
| Dec 2025 | 71.51% | - | 0% | 0% | 28.49% |
| Sep 2025 | 71.51% | - | - | - | 28.49% |
| Jun 2025 | 71.51% | - | - | - | 28.49% |
| Mar 2025 | 71.51% | - | - | - | 28.49% |
| Dec 2024 | 71.51% | - | - | - | 28.49% |
| Sep 2024 | 71.51% | - | - | - | 28.49% |